Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cell-based therapeutics - Q Therapeutics

Drug Profile

Research programme: cell-based therapeutics - Q Therapeutics

Alternative Names: Astrocyte-based therapeutics - Q Therapeutics; Glial cell-based therapeutic (Q-Cells) - Q Therapeutics; Q-Cells; Transplanted human GRPs - Q Therapeutics

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Utah
  • Developer Drexel University College of Medicine; Johns Hopkins University; Q Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Transverse myelitis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Demyelinating disorders; Spinal cord injuries

Most Recent Events

  • 01 Oct 2018 Q Therapeutics enters into a research collaboration with InVivo Therapeutics for development of adult neural progenitor cells and induced pluripotent stem cells for CNS disorders
  • 01 Oct 2018 Research programme: cell-based therapeutics - Q Therapeutics receives Fast Track designation for Amyotrophic lateral sclerosis in USA before October 2018
  • 01 Oct 2018 Q Therapeutics plans a phase I/II trial in Transverse myelitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top